FDA Panel Okays Purdue's Newer OxyContin, But Is Still Hung Up On Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee members said a newer formulation of OxyContin may deter misuse, but its safety is unclear.
You may also be interested in...
Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?
FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.
Naproxcinod Gets Joint Advisory Committee; Will It Lower NicOx's Blood Pressure?
FDA's decision to include both Arthritis Drugs and Risk Management panels in May 12 review suggests focus will on cardiovascular risks of the osteoarthritis drug.
Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead
FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.